Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07224880

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Sponsor: Cytrellis Biosystems, Inc.

View on ClinicalTrials.gov

Summary

The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity

Official title: Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series

Key Details

Gender

All

Age Range

30 Years - 65 Years

Study Type

OBSERVATIONAL

Enrollment

10

Start Date

2025-10-14

Completion Date

2026-02-28

Last Updated

2025-12-31

Healthy Volunteers

No

Interventions

DEVICE

ellacor

dermal non-thermal micro-coring device

Locations (1)

Tri Valley Plastic Surgery

Dublin, California, United States